Neurotargeting Group members
Hovedinnhold
Students in the group
2023/2024
Lise Skarstein (Aug 2023 – present) Investigating neurobiological markers using fMRI for treatment response to concentrated exposure treatment in Obsessive Compulsive Disorder and general anxiety disorders. | |
Risha Chowdhury (Aug 2023 – present) Investigating the molecular effects of CMT-linked missense mutations on GDAP1 and obtaining new structural and functional data on CNPase. | |
2022/2023
Mar Trinidad Fernandez (Feb 2023 – present) Explore the selective but indirect inhibition of NaV1.7, via regulation of CRMP2 using small-molecule compounds, aiming for a new therapeutic approach for chronic pain. For this, I will be following Lisa Reinmuth's research. | |
Sarah Weber (Sep 2022 – Dec 2022) | |
Sofie Breisnes Wormdahl (Aug 2022 – present) Investigate possible changes in the interaction between tyrosine hydroxylase and 14-3-3 in response to hyperoxia and simulated diving. | |
Aiza Ashfaq (Aug 2022 – Jun 2023) | |
José Miguel Godoy Muñoz (Aug 2022 – Jun 2023) Nanobody-aided structural study of activity-regulated cytoskeleton-associated protein (Arc), a multifunctional regulator of synaptic plasticity. | |
Lasse Neset (May 2022 – Jun 2023) Structural and functional studies of activity-regulated cytoskeleton-associated (Arc) protein, using high-affinity nanobodies. |
2021/2022
Lucia Wagner (Sep 2021 – Jun 2022) Investigating the effects of electroconvulsive therapy on the brain's motor coordination and the blood-brain barrier. | |
Tone Hestad Valland (Sep 2021 – Jun 2022) She tests different unique natural compounds to see if they can be new drug candidates based on the interaction with the protein Annexin A2. | |
Elma Cerimagic (Sep 2021 – Jun 2022) She will be looking at eight different natural compounds to see how they affect cell viability, wound healing and the expression of annexin A2 in PC12 cells. | |
Inger-Lise Fleisje (Sep 2021 – Jun 2022) | |
Marcel Schröder (Sep 2021 – Feb 2022) Biochemical and structural characterization of an interaction between an ultra-high affinity camelid nanobody and an abundant myelin enzyme of the central nervous system. | |
José Miguel Godoy Muñoz (Aug 2021 – Oct 2021) Planning, execution, and analysis of routine experiments related to the production and characterisation of recombinant myelin proteins (quality assessments, binding assays, structural determinations). |
2020/2021